Dan Schell articles

  1. The Changing Business Of Drug Development 10/14/2009

    It has been said that one of the key changes pharma companies will need to make is to adopt more rapid drug development processes with the intention to eliminate unsuccessful compounds sooner and promote successful ones more quickly. Do you agree with this assumption?

  2. Technology Roundtable: EDC (Electronic Data Capture) 10/14/2009

    How Do You Define EDC? Does It Start With An eCRF, Or Can It Start With A Physical CRF? By Dan Schell, Life Science Leader magazine

  3. What To Look For In A Functional Service Provider 10/1/2009

    I recently sat down with Eleanore Doyle, group VP for Kforce Clinical Research (www.kforce.com/clinicalresearch), to discuss the increasing dependence on functional service providers (FSPs). These firms perform specific functions during clinical studies, such as study monitoring and data management, assuming complete control of these functions. Meanwhile, the sponsor maintains overall management and control of the study.

  4. Future Life Science Challenges & Trends 10/1/2009

    Nigel Darby, general manager for biotechnologies and chief technical officer at GE Healthcare Life Sciences, comments in this exclusive interview with Life Science Leader on some of the key issues affecting life science executives.

  5. Better Quantifying Clinical Trial Costs 10/1/2009

    A few years ago, I bet a lot of pharmaceutical companies felt they were being cost-conscious when it came to drug development. They probably thought their processes and operations were as streamlined and efficient as possible. But we all know now that this industry has changed, and with that change has come a higher set of expectations regarding expenses and efficiencies — especially when it comes to drug development.

  6. Innovation & Money 10/1/2009

    I’m no expert on healthcare reform, but I doubt any of our readers would support a plan that directly retards innovation in the life sciences industry. But, since innovation takes money, I’ll bet you could argue that almost any plan that includes some form of fees or taxes for life sciences companies will hamper innovation either directly or indirectly. That’s a tough realization considering our industry already has a dearth of funding sources for up-and-coming biotechs and is rife with company closures.

  7. I Hear You 10/1/2009

    In early October I posted the first Life Science Leader LinkedIn poll, which had a single question: What are your favorite topics for life science-related articles? As of press time, about 50 people had taken the poll with the majority favoring pharma/biotech success stories (much like the article on Lux Biosciences on page 8). Although a small response rate, these results still helped validate that the editorial subjects we focused on during our first publication year were, in fact, interesting to our readers.

  8. The Transformation Of Sanofi-Aventis U.S. 9/17/2009

    The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. By Dan Schell, Life Science Leader magazine

  9. Help For Small Biotech/Pharma 9/1/2009

    We’ve all heard the disheartening stories about the throngs of small biotech/pharma firms that have folded due to the economy and how the outlook isn’t much better for the near future. However, last month the FDA released a new rule that could be the ray of hope some of these financially struggling companies have been looking for.

  10. A View From The Top: Q&A With AstraZeneca CEO David Brennan 7/29/2009

    In 2008, AstraZeneca helped more than 440,000 people save more than $612M on their medicines through our prescription savings programs.